WO2023091852A1 - Vaso-occlusive devices and methods for making and using same - Google Patents

Vaso-occlusive devices and methods for making and using same Download PDF

Info

Publication number
WO2023091852A1
WO2023091852A1 PCT/US2022/078935 US2022078935W WO2023091852A1 WO 2023091852 A1 WO2023091852 A1 WO 2023091852A1 US 2022078935 W US2022078935 W US 2022078935W WO 2023091852 A1 WO2023091852 A1 WO 2023091852A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaso
distal
wire
coil
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/078935
Other languages
English (en)
French (fr)
Inventor
Esther KOO
Clifford Teoh
Stella Than CHU
Jason DELGADILLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker European Operations Ltd
Stryker Corp
Original Assignee
Stryker European Operations Ltd
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker European Operations Ltd, Stryker Corp filed Critical Stryker European Operations Ltd
Priority to ES22831035T priority Critical patent/ES3024240T3/es
Priority to JP2024529178A priority patent/JP2024540455A/ja
Priority to CN202280071603.3A priority patent/CN118175965A/zh
Priority to EP22831035.5A priority patent/EP4432932B1/en
Publication of WO2023091852A1 publication Critical patent/WO2023091852A1/en
Priority to US18/667,790 priority patent/US20240299035A1/en
Anticipated expiration legal-status Critical
Priority to US19/195,670 priority patent/US20250255611A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/12Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/12Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A61B17/12113Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/12Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/1214Coils or wires
    • A61B17/12145Coils or wires having a pre-set deployed three-dimensional shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/12Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/12031Type of occlusion complete occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B2017/00526Methods of manufacturing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B2017/00831Material properties
    • A61B2017/00867Material properties shape memory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/12Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12063Details concerning the detachment of the occluding device from the introduction device electrolytically detachable

Definitions

  • the present disclosure relates generally to medical devices and intravascular medical procedures and, more particularly, to devices for occluding vascular defects, such as aneurysms and methods for making and using such devices.
  • Vaso-occlusive devices or implants are used for a wide variety of reasons, including treatment of intra-vascular aneurysms.
  • An aneurysm is a dilation of a vessel, such as a blood vessel, that may pose a risk to a patient’s health due to rupture, clotting, or dissection.
  • rupture of an aneurysm in a patient’s brain may cause a stroke, and lead to brain damage and death.
  • Cerebral aneurysms may be detected in a patient, e.g., following seizure or hemorrhage, and may be treated by applying vaso-occlusive devices.
  • vaso-occlusive devices include soft, helically wound coils formed by winding a platinum (or platinum alloy) wire strand about a “primary” mandrel. The coil is then wrapped around a larger, “secondary” mandrel, and heat treated to impart a secondary shape.
  • a vaso-occlusive device that assumes a linear, helical primary shape when stretched for placement through the lumen of a delivery catheter, and a folded, convoluted secondary shape when released from the delivery catheter and deposited in the vasculature.
  • complex three-dimensional secondary shapes can be imparted on vaso-occlusive devices and the stiffness/flexibility of vaso-occlusive devices can be modified.
  • a small profile delivery catheter or “micro-catheter” In order to deliver the vaso-occlusive devices to a desired site in the vasculature, e.g., within an aneurysmal sac, it is known to first position a small profile delivery catheter or “micro-catheter” at the site using a guidewire.
  • the distal end of the micro-catheter is provided, either by the attending physician or by the manufacturer, with a selected preshaped bend, e.g., 45°, 26°, “J”, “S”, or other bending shape, depending on the particular anatomy of the patient, so that it will stay in a desired position for releasing one or more vaso-occlusive device(s) into the aneurysmal sac once the guidewire is withdrawn.
  • a delivery or “pusher” assembly or “wire” is then passed through the micro-catheter until a vasoocclusive device coupled to a distal end of the delivery assembly is extended out of the distal end opening of the micro-catheter and into the aneurysmal sac. Once in the aneurysmal sac, portions of the vaso-occlusive device may deform or bend to allow more efficient and complete packing. The vaso-occlusive device is then released or “detached” from the distal end of the delivery assembly, and the delivery assembly is withdrawn back through the micro-catheter. Depending on the particular needs of the patient, one or more additional vasoocclusive devices may be pushed through the micro-catheter and released into the same aneurysmal sac.
  • vaso-occlusive devices are typically used to visualize vaso-occlusive devices during delivery into an aneurysm, while magnetic resonance imaging (MRI) is typically used to visualize the treatment site post-procedure (e.g., a few weeks after initial treatment of the aneurysm) to ensure that the aneurysmal sac is properly occluded.
  • MRI magnetic resonance imaging
  • vasoocclusive devices be constructed in a manner that enables their radiopacity during treatment of the aneurysm, while minimizing any visualization obscuring artifacts created during the post-procedure MRI (i.e., being MRI-compatible). It is also preferable that such vasoocclusive devices be “soft” (i.e., be laterally flexible or conformable), and thus atraumatic, to prevent rupturing of the delicate tissues of the aneurysm.
  • vaso-occlusive devices be chronically retained within the aneurysm.
  • aneurysms with larger mouths commonly known as “wide neck aneurysms”
  • small aneurysms e.g., aneurysm having diameters less than about 7 mm, or even smaller such as less than about 5 mm
  • Fig. 1 depicts a portion of a vasoocclusive coil herniating out of the aneurysm after implantation. To alleviate coil herniation during placement, several placement techniques have been developed.
  • a “jailing technique” utilizes a balloon or stent deployed in the vessel adjacent to the neck region of the aneurysm to prevent the vaso-occlusive coils from exiting the aneurysmal sac.
  • Fig. 2 depicts the jailing technique using a balloon activated catheter.
  • the balloon activated catheter is used to deploy a balloon adjacent to the neck region of the aneurysm.
  • the balloon prevents coils from herniating from the aneurysm as the latterare implanted into the aneurysm.
  • this technique creates a risk of the balloon pushing the tip of the catheter into the dome of the aneurysm and rupturing the aneurysm.
  • FIG. 3 depicts a jailing technique using a stent.
  • the stent is placed and expanded around the neck of the aneurysm to block the coils from exiting the aneurysm sac. Similar to the balloon activated catheter, the stent technique also risks the stent pushing the tip of the catheter into the dome of the aneurysm and rupturing the aneurysm.
  • Fig. 4 depicts another placement technique for implanting a vaso-occlusive device called “recrossing.” In this technique, the delivery catheter extends through an opening in the stent. The stent prevents the coils from herniating out of the aneurysm sac. However, due to inherent unpredictability of positioning the delivery catheter through an opening of the stent, there is a risk that manipulation of the delivery catheter to direct and position the delivery catheter can cause the catheter tip to push into the dome thereby rupturing the aneurysm.
  • vaso-occlusive coils have been developed which provide more neck coverage and shape stability to effectively “frame” an aneurysm.
  • the three-dimensional shapes of current vaso-occlusive devices are either not conducive to framing or are prone to herniation during deployment into an aneurysm.
  • Small aneurysms are best treated with as few coils as possible and current vasoocclusive devices are not able to balance shape stability and softness as a standalone unit.
  • the shapes and configuration of current vaso-occlusive devices result in a directly proportional relationship between shape stability and softness.
  • the softer the device i.e., the less resistant to deformation from an external force
  • the less stable the device i.e., the less soft the device, the more stable the shape of the vasoocclusive device.
  • a softer coil is less likely to rupture an aneurysm but is not able to retain its shape such that it is more prone to herniation out of the aneurysm during deployment and/or retention.
  • a stiffer coil is better able to retain its shape and frame the aneurysm, but imparts higher stresses on the aneurysm wall, creating high risk of rupturing the aneurysm, especially small aneurysms with a high rupture risk.
  • the initial distal loops e.g., first and second loops
  • the initial distal loops have a higher likelihood of herniating out of the aneurysm due to subsequent loops pushing them out during deployment.
  • vaso-occlusive devices which can alleviate the issues of herniation during placement and retention and provide effective framing of the aneurysm, and at the same time have a sufficiently soft and pliable structure that will not rupture the aneurysm, especially small, wide-necked aneurysms.
  • a vaso-occlusive device comprises an elongate vasoocclusive device (e.g., from 0.5 to 100 cm in length) configured for implantation in an aneurysm sac.
  • the vaso-occlusive devices disclosed herein are not limited to being configured and used for treating small, wide-necked aneurysms, but they are particularly well-suited for such configuration and use.
  • the vaso-occlusive device typically has a delivery configuration (having a primary shape) when restrained within a delivery catheter and a deployed configuration (having a secondary shape different from the primary shape) when released from the delivery catheter into the aneurysmal sac.
  • the vaso-occlusive device includes wire having a primary configuration in a constrained condition.
  • the primary configuration may be a shape of the wire when it is constrained within a delivery catheter, such as a helical coil shape, linear shape, or the like.
  • the wire is also configured to form into a secondary configuration in a relaxed, unconstrained condition, such as when the wire is released from a delivery catheter with no external forces exerting on the wire.
  • the secondary configuration of the wire provides a balanced solution between shape stability and softness such that the vaso-occlusive device has a stable shape which prevents herniation during deployment and retention and provides effective framing of the aneurysm, while also having sufficient softness/pliability to avoid rupturing the aneurysm.
  • the pyramidal shape has an inherent ability to effectively dissipate forces applied to its apexes, thereby reducing the risk of imparting excessive forces on the walls of the aneurysm which could rupture the aneurysm.
  • the secondary configuration includes a pyramidal portion comprising a plurality of distal coils wound from the wire.
  • Each distal coil includes a winding forming a closed loop of greater than 360° wherein the winding has a perimeter which tapers outwardly from an interior of the pyramidal portion
  • the diameter of the coil tapers outwardly such that the interior part of the loops of the coil has a smaller diameter than outer part of the loops of the coil.
  • Each distal coil also includes a transition segment of the wire between and connecting each distal coil to one or more adjacent distal coils.
  • the plurality of distal coils is arranged in a pyramidal shape such that each coil is parallel to, and lies in, a different lateral face of the pyramidal shape. For clarity, there is not a distal coil lying in the base of the pyramidal shape.
  • the pyramidal shape may be a tetrahedron having a base with 3 sides connected to an apex with each base side and the apex forming a triangle wherein each triangle defines one of the 3 lateral faces.
  • the body portion described below may form the base portion of the pyramidal shape.
  • the secondary configuration also has a body portion proximal of the pyramidal portion.
  • the body portion comprises a coil formed from the wire and extending proximally from the pyramidal portion.
  • the body portion may extend proximally from the position of the base of the pyramidal shape.
  • the pyramidal shape is a polyhedral shape formed of a polygonal base having n number of sides and n number of lateral faces connecting to an apex, such as a tetrahedral shape (triangular base and 3 lateral faces, also referred to as a triangular pyramid), pentahedral shape (quadrilateral base and 4 lateral faces, also referred to as a square or rectangular pyramid), hexahedral shape (pentagonal base and 5 lateral faces, also referred to as a pentagonal pyramid), etc.
  • a tetrahedral shape triangular base and 3 lateral faces, also referred to as a triangular pyramid
  • pentahedral shape quadrilateral base and 4 lateral faces, also referred to as a square or rectangular pyramid
  • hexahedral shape pentagonal base and 5 lateral faces, also referred to as a pentagonal pyramid
  • each of the distal coils comprises at least 1-2/3 loops or turns (winding of 600°), or from 1-2/3 loops to 2-2/3 loops (winding of °).
  • the distal coils are overlapping in the transition from one distal coil to an adjacent distal coil. In other words, the transition segment overlaps the coil as it extends from one distal coil to a subsequent, adjacent coil.
  • the primary configuration comprises an elongate helical coil.
  • the helical coil has an outside diameter (OD) configured to fit within the lumen of a suitable delivery catheter for deploying the catheter.
  • OD outside diameter
  • the elongate helical coil has zero pitch between each loop of the coil which provides the most compact coil.
  • the elongate helical coil may have a non-zero pitch, or even a varying pitch.
  • the wire may be formed from a shape memory material, and the secondary configuration is set by winding the wire on a mandrel and heat treating the wire wound on the mandrel.
  • each of the distal coils has a coil diameter (the diameter of the inner most loop of each distal coil) between 10 to 90 percent of a diameter of an aneurysm the device is designed to treat, or alternatively, a coil diameter (the diameter of the inner most loop of each distal coil) between 55 to 85 percent of a diameter of an aneurysm the device is designed to treat.
  • the primary shape has a longitudinal length of from 1 to 70 cm.
  • a mandrel for forming the vaso-occlusive device comprises a central, spherical element.
  • a plurality of distal coil posts extend from the central, spherical element.
  • the distal coil posts are spaced angularly around the spherical element.
  • Each distal coil post has a cross-sectional diameter which tapers outwardly as the distal coil post extends away from the spherical element.
  • Each distal coil post also has a longitudinal axis which is oriented such that respective planes perpendicular to each respective longitudinal axis have an intersection which forms a pyramidal shape having an apex distal to the distal coil posts.
  • the mandrel also has a body post extending from the spherical element.
  • the body post extends proximally from the spherical element.
  • a wire having a primary configuration is then wound around the mandrel.
  • the wire may be formed of a shape memory material.
  • the primary configuration may be a configuration of the wire in a constrained condition, such as within a sheath or delivery catheter, and can have any suitable shape, such as a helical coil.
  • the wire is wound around a first distal coil post of the plurality of distal coil posts in a first direction and winding inward towards the intersection of the first distal coil post and the spherical element and forming at least 360°, or at least 1-2/3 first loops (600°) around the first distal coil post.
  • a winding “direction” is relative to viewing inwardly along the winding axis toward the position of the attachment of a winding post to the central, spherical element or other central structure.
  • the wire After winding the wire around the first distal coil post, the wire is traversed along the spherical element in a first transition segment to a next distal coil post immediately adjacent to the first distal coil post of the plurality of posts.
  • the wire is then wound around the next distal coil post in a second direction opposite to the first direction starting at the intersection of the next distal coil post and the spherical element forming at least 1-2/3 next loops around the next distal coil post, and then traversing along the spherical element in a next transition segment to a subsequent distal coil post immediately adjacent to the preceding distal coil post.
  • the wire as wound around the mandrel is heat treated to set a secondary configuration of the vasoocclusive device.
  • the secondary configuration is a relaxed, unconstrained configuration of the wire.
  • the secondary configuration comprises a pyramidal portion and a body portion proximal of the pyramidal portion.
  • the pyramidal portion comprises a plurality of distal coils wound from the wire on respective distal coil posts.
  • Each distal coil comprises a winding forming a closed loop of greater than 360°, or at least 1-2/3 loops, wherein the winding has a perimeter which tapers outwardly from an interior of the pyramidal portion.
  • the plurality of distal coils are arranged in a pyramidal shape such that each coil lies in a different lateral face of the pyramidal shape.
  • the body portion is proximal of the pyramidal portion, and comprises a coil formed from the wire wound on the body post, and extends proximally from the pyramidal portion.
  • the pyramidal shape is a polyhedral shape formed of a polygonal base having n number of sides and n number of lateral faces connecting to an apex, such as a tetrahedral shape (triangular base and 3 lateral faces, also referred to as a triangular pyramid), pentahedral shape (square/quadrilateral base and 4 lateral faces, also referred to as a square pyramid), hexahedral (pentagonal base and 5 lateral faces, also referred to as a pentagonal pyramid), etc.
  • a tetrahedral shape triangular base and 3 lateral faces, also referred to as a triangular pyramid
  • pentahedral shape square/quadrilateral base and 4 lateral faces, also referred to as a square pyramid
  • hexahedral pentagonal base and 5 lateral faces, also referred to as a pentagonal pyramid
  • each of the distal coils comprises at least 1-2/3 loops or turns, or from 1-2/3 loops to 2 loops.
  • each transition segment crosses over at least part of the loops from which the transition segment is transitioning such that the distal coils are overlapping in the transition from one distal coil to an adjacent distal coil. In other words, the transition segment overlaps the coil as it extends from one distal coil to a subsequent, adjacent coil.
  • the primary configuration comprises an elongate helical coil.
  • the helical coil has an outside diameter (OD) configured to fit within the lumen of a suitable delivery catheter for deploying the catheter.
  • OD outside diameter
  • the elongate helical coil has zero pitch between each loop of the coil which provides the most compact coil.
  • the elongate helical coil may have a non-zero pitch, or even a varying pitch.
  • each post may have a cross-sectional diameter which tapers outwardly as the post extends away from the spherical element at an angle between about 5 to 15 degrees, or between about 1 to 30 degrees.
  • the vaso-occlusive devices disclosed herein may be a part of a vaso-occlusive system comprising a vaso-occlusive assembly and a delivery assembly.
  • a vaso-occlusive assembly may comprise any of the vaso-occlusive devices described herein, and a pusher member detachably coupled to a proximal end of the vaso-occlusive device.
  • the pusher member is configured to allow a clinician to advance the vaso-occlusive device along a delivery catheter through a patient’s vasculature to a target site, such as an aneurysm being treated with the vaso-occlusive device, and to push the vaso-occlusive device out of the distal end of the delivery catheter to deploy the vaso-occlusive device.
  • the vaso-occlusive assembly may also include a detachment device detachably coupling the pusher member to the vaso-occlusive device.
  • the detachment device may comprise an electrolytic detachment, mechanical connector, heat activated detachment, dissolving detachment, etc.
  • the delivery assembly may include a delivery catheter into which the vaso-occlusive device may be installed in its compact, delivery configuration.
  • the delivery assembly may also include a guidewire for guiding the delivery catheter to a target implantation site within a patient’s vasculature, such as an aneurysm. The guidewire is then be removed, and the vaso-occlusive device is advanced through the delivery catheter to the target implantation site.
  • the devices disclosed herein are not limited to being vaso-occlusive devices, but may be any medical device comprising the same or similar structure of the vaso-occlusive devices disclosed herein.
  • the medical device may be any suitable thrombectomy device, stent retriever, embolic filter, stent delivery system, other implantation device, guidewire, intravascular device, or other medical device.
  • the vaso-occlusive device is deployed using a delivery catheter.
  • the delivery catheter is first inserted into the patient’s vasculature and is advanced within the vasculature to position the distal end of the delivery catheter at the target insertion site.
  • the target insertion site is an aneurysm. It is understood that the target insertion site may be any suitable anatomical site or cavity within the vasculature into which the vaso-occlusive device is being deployed.
  • the guidewire is first inserted into the patient’s vasculature and advanced through the vasculature to the site of the aneurysm. Then, the delivery catheter is advanced along the guidewire to the aneurysm, and then the guidewire is removed.
  • the vaso-occlusive device is then inserted in its compact, delivery configuration into the delivery catheter and advanced along the delivery catheter until the distal end of the vaso-occlusive device is positioned at the target insertion site.
  • the vaso-occlusive device is then pushed distally out of the delivery catheter, such as by using a pusher-member detachably attached to the proximal end of the vaso-occlusive device.
  • the portions of the vaso-occlusive device in its compact, delivery configuration e.g., a helical coil
  • comprising the distal coils of the vaso-occlusive device are first advanced out of the delivery catheter and into the aneurysmal sac.
  • portions comprising the distal coils exit the delivery catheter and enter the aneurysm, such portions assume the secondary configuration comprising the distal coils.
  • the vaso-occlusive device continues to be advanced out of the delivery catheter, the body portion is also advanced into the aneurysmal sac. Once the entire vasoocclusive device is inserted into the aneurysmal sac, the vaso-occlusive device may be detached from the pusher-member, such as by actuating or activating the detachment device.
  • the vaso-occlusive device in its secondary configuration has a stable shape with inward facing loops. Due to the outwardly tapering diameter, the loops or turns of each of the distal coils are inward facing.
  • the surface of the loops faces inward toward the geometric interior of the pyramidal shape of the pyramidal portion.
  • the inward facing loops tend to avoid herniating out of the aneurysm during deployment and retention, and the pyramidal configuration of the distal coils also provides shape stability which effectively frames the aneurysm while also exhibiting a soft and pliable structure which avoids imparting excessive forces on the walls which could rupture the aneurysm.
  • a single vaso-occlusive device may be sufficient to fill and occlude the aneurysm. If multiple vaso-occlusive devices are needed, this process may be repeated to deliver a sufficient number of vaso-occlusive devices to fill and occlude the aneurysm.
  • vaso-occlusive devices which can alleviate the issues of herniation during placement and retention and provide effective framing of the aneurysm, and at the same time have a sufficiently soft and pliable structure that will not rupture the aneurysm, especially small, wide-necked aneurysms.
  • FIG. 1 is a side, cross-sectional view of a delivery catheter deploying a vasoocclusive device in which the vaso-occlusive device is herniating.
  • FIG. 2 is cross-sectional, side view of a delivery catheter deploying a vasoocclusive device and a balloon activated catheter used in a jailing technique.
  • FIG. 3 is a cross-sectional, side view of a delivery catheter deploying a vasoocclusive device and a stent used in a jailing technique.
  • FIG. 4 is a cross-sectional, side view of a delivery catheter deploying a vasoocclusive device and a stent used in a recrossing technique.
  • FIG. 5 is a side, perspective view of a vaso-occlusive device in a relaxed, deployed configuration.
  • FIG. 6 is a top perspective view of a simplification of the intersecting planes of the 3 distal coils of FIG. 5 forming the pyramidal portion of the vaso-occlusive device in the shape of a triangular pyramid.
  • FIG. 7 is a top perspective view of a simplification of the intersecting planes of 4 distal coils forming the pyramidal portion of a vaso-occlusive device in the shape of a square pyramid.
  • FIG. 8 is a side view of distal coil post for forming the distal coils illustrating the taper angle for the loops of a coil.
  • FIG. 9 is a side, perspective view of an example of an alternative pyramidal portion of the vaso-occlusive device of FIG. 5 in which the distal coils have varying diameters and varying numbers of turns.
  • FIG. 10 is a side, perspective view of an exemplary mandrel for making the vasoocclusive device of FIG. 5.
  • FIG. 11 is a side, perspective view of an exemplary mandrel for making a vasoocclusive device having 4 distal coils forming the pyramidal portion in the shape of a square pyramid.
  • FIG. 12A is a top, perspective view of the mandrel of FIG. 10 with a wire wound around the mandrel to make the vaso-occlusive device of FIG. 5.
  • FIG. 12B is a side, perspective view of the mandrel of FIG. 12A with the wire wound around the mandrel to make the vaso-occlusive device of FIG. 5.
  • FIG. 13 is a flow chart showing a method of making the vaso-occlusive devices described herein using the mandrels described herein.
  • FIG. 14A is a cross-sectional side view of a vaso-occlusive system including the vaso-occlusive device of FIG. 5 in its restrained, delivery configuration within a delivery catheter.
  • FIG. 14B is a cross-sectional, side view of the vaso-occlusive system of FIG. 14A with the vaso-occlusive device deployed out of the delivery catheter and in its expanded, deployed configuration.
  • FIG. 15 a cross-sectional, side view depicting a guidewire advanced into a portion of a patient’s vasculature to the location of an aneurysm.
  • FIG. 16 is a cross-sectional, side view depicting the guidewire and patient’s vasculature of FIG. 15 with a delivery catheter advanced over the guidewire.
  • FIG. 17 is a cross-sectional, side view depicting the vaso-occlusive system of FIGS. 14A and 14B being advanced within the delivery catheter of FIG. 16 for deploying the vaso-occlusive device into the aneurysm.
  • FIG. 18 is a cross-sectional, side view depicting the vaso-occlusive system of FIGS. 14A and 14B with the vaso-occlusive device deployed out of the delivery catheter shown in FIG. 16 and into the aneurysm.
  • FIG. 19 is a flow chart of an exemplary method of using the vaso-occlusive system of FIGS. 14A and 14B to deploy the vaso-occlusive devices disclosed herein into an aneurysm.
  • FIG. 5 depicts the vaso-occlusive device 100 in its secondary configuration in a relaxed, unconstrained condition.
  • FIG. 5 shows the vasoocclusive device 100 when there are no external forces exerting on the vaso-occlusive device 100.
  • the secondary configuration of the vaso-occlusive device 100 has a distal pyramidal portion 104 and a proximal body portion 106, such that the distal pyramidal portion 104 is distal to the proximal body portion 106.
  • distal and proximal are relative to the vaso-occlusive device 100 as it is intended to be deployed, wherein the term “distal” refers to being situated toward the end of the device 100 which is inserted first, and “proximal” refers to being situated toward the end of the device 100 which is inserted last.
  • the vaso-occlusive 100 comprises a wire 102 having a primary configuration in a constrained configuration.
  • the constrained configuration may be an elongate, helical coil when the wire 102 is constrained within a delivery catheter (see FIG. 14A).
  • the primary shape has a longitudinal length between 1 cm to 70 cm.
  • the wire 102 is made from any suitable material, but typically comprises a radiopaque, shape memory material, such as the platinum group metals, including platinum, rhodium, palladium, and rhenium, as well as tungsten, gold, silver, tantalum, and alloys of these metals.
  • the pyramidal portion 104 in the secondary configuration of the vaso-occlusive device 100 is formed by a distal portion of the vaso-occlusive device 100 in its primary configuration (see FIG. 14 A).
  • the pyramidal portion 104 includes a plurality of distal coils 108 wound from the wire 102. In the illustrated example of FIG.
  • the pyramidal portion 104 includes three distal coils 108a, 108b, and 108c, arranged to form a pyramidal shape having three lateral faces, also referred to as a triangular pyramid as the base (the distal coils 108 do not include a distal coil at the base of the pyramidal shape) is a triangle, wherein a respective coil 108 lies in each lateral face of the triangular pyramid.
  • the respective planes in which each distal coil 108 lies are non-parallel and intersect with each other.
  • a simplification of the intersecting planes of the distal coils 108 forms a tetrahedral, more specifically, a triangular pyramid.
  • the vaso-occlusive device 100 may have distal coils 108 in each lateral face of a pyramidal shape which may be a square pyramid having a square base and 4 lateral faces, a quadrilateral pyramid having a quadrilateral base and 4 lateral faces, a pentagonal pyramid having a pentagonal base and 5 lateral faces, etc.
  • the pyramidal portion 104 may have 4 distal coils 108 in each lateral face arranged to form a square pyramid having a square base and 4 lateral faces.
  • each distal coil 108 includes a winding forming a closed loop of greater than 360°, i.e., at least a complete, closed loop.
  • each distal coil 108 includes a winding of 1-2/3 loops (also referred to as “turns”), which is equivalent to a winding of 600°.
  • each distal coil 108 may have at least 1-2/3 turns, or between 1-2/3 turns (600°) and 2 turns (720°).
  • each of the distal coils 108 also has a width which tapers outwardly from a reference point of the interior of the pyramidal portion.
  • the width of each distal coil 108 is the diameter of the coil. If the distal coils 108 are wound in a different shape, such as a square, pentagon, or other polygonal or curved shape, the width may be an average width, such an average of the maximum and minimum width drawn through the geometric center of the shape. Turning the example of FIG. 5, the diameter of each distal coil 108 tapers such that the diameter of the outer part of the coil 108 is larger than the diameter of the inner part of the coil 108.
  • the post has a diameter which tapers outwardly from the inner part of the post to the outer part of the post, as depicted in FIG. 8.
  • the angle 114 of the post taper defines the angle of the taper of the distal coil 108 in the secondary configuration of the vaso-occlusive device 100. Due to the outwardly tapering diameter, the loops or turns of each of the distal coils 108 is inward facing. In other words, the surface of the loops faces inward toward the geometric interior of the pyramidal shape of the pyramidal portion 104.
  • Each of the distal coils 108 has a diameter (defined as the diameter of the inner most loop of each distal coil 108) between 10 to 90 percent of a diameter of an aneurysm the vaso-occlusive device 100 is designed to treat.
  • the diameter of each distal coil 108 may be between 55 to 85 percent of a diameter of an aneurysm the vaso-occlusive device 100 is designed to treat.
  • the distal coils 108 may have differing diameters and/or differing numbers of turns of the wire 102, as illustrated in FIG. 9.
  • the first distal coil 108a has a larger diameter and more turns of the wire 102 (3 turns, i.e., 1080°) than the second distal coil 108b which has 1-2/3 turns (600°).
  • the third distal coil 108c also has a larger diameter than the second distal coil 108b (same diameter as the first distal coil 108a and 1-2/3 turns (600°).
  • the pyramidal portion 104 also includes a respective transition segment 110 of the wire 102 which is between and connecting each adjacent distal coil 108 to each other.
  • Each transition segment 110 extends from the ending of one distal coil 108 to the beginning of the subsequent distal coil 108.
  • the transition segment 110a extends from the ending of the distal coil 108a to the beginning of the distal coil 108b
  • the transition segment 110b extends from the ending of the distal coil 108 to the beginning of the distal coil 108c.
  • the body portion 106 comprises a winding of the wire 102 which extends proximally from the pyramidal shape 104.
  • the body portion 106 may extend from the imaginary base of the pyramidal shape of the pyramidal portion 104.
  • the body portion 106 is a helical coil extending proximally from the pyramidal portion 104.
  • the body portion 106 may have a constant diameter, or alternatively, the body portion 106 may have a diameter which tapers outwardly or inwardly as it extends from the proximally from the pyramidal portion 104.
  • the body portion 106 comprises at least one full loop of the wire 102.
  • the body portion 106 does not have a maximum degree of winding and may include any suitable number of turns, such as between 1 and 20 turns.
  • the body portion 106 depicted in FIG. 5 has about 2 full turns of the wire 102.
  • the body portion 106 depicted in FIG. 9 has about 4 full turns of the wire 102.
  • FIG. 10 an exemplary mandrel 200 for making the vaso-occlusive device 100 using a method 300 (described below) is illustrated.
  • the mandrel 200 is used to wind the wire 102 around to form the secondary configuration of the vaso-occlusive device 100.
  • the mandrel 200 is configured to form a vaso-occlusive device 100 comprising a pyramidal portion 104 having a triangular pyramid shape.
  • the mandrel 200 has a central, spherical element 202.
  • a plurality of distal coil posts 204 extend outwardly from the central spherical element 202.
  • the distal coil posts 204 are configured to form the distal coils 108 of the vaso-occlusive device 100.
  • the distal coil posts 204 are spaced angularly around the spherical element 202.
  • the distal coil posts 204 are evenly spaced such that a respective longitudinal axis of each distal coil is evenly, angularly spaced around the spherical element 202. Accordingly, in the case of three distal coil posts 204, the distal coil posts 204 are spaced apart by 120°.
  • Each distal coil post 204 has a cross-sectional diameter which tapers outwardly as the distal coil post 204 extends away from the spherical element 202, as shown in FIG. 8 which shows a side view of one of the distal coil posts 204.
  • the angle 114 of the taper of the distal coil posts 204 is the same as the taper of the distal coils 108, described herein.
  • the longitudinal axis of each distal coil post 204 is also canted distally such that respective planes perpendicular to each respective longitudinal axis are non-parallel and non-perpendicular and the planes have an intersection which forms a pyramidal shape having an apex distal to the distal coil posts 204.
  • the mandrel 200 also has a body post 206 extending from the spherical element 202.
  • the body post 206 is configured to form the body portion 106 of the vaso-occlusive device 100.
  • the body post 206 extends proximally from the spherical element 202 and perpendicular to the base of the pyramidal shape.
  • the body post 206 may be a cylinder having a constant diameter, or alternatively, the body post 206 may taper outwardly or inwardly as it extends from the spherical element 202.
  • FIG. 11 shows a mandrel 210 which is configured to make a vasoocclusive device 100 comprising a pyramidal portion 104 having a square pyramid shape.
  • the mandrel 210 is same or substantially similar to the mandrel 200, except that the mandrel 210 has four distal coil posts 204 evenly, angularly spaced around the central, spherical member 202.
  • a wire 102 having a primary configuration is wound around the mandrel 300.
  • the wire 102 may be formed of a shape memory material, and the primary configuration may be a configuration of the wire 102 in a constrained condition, such as within a sheath or delivery catheter.
  • the primary configuration may have any suitable shape, such as a helical coil.
  • the wire 102 is first wound around the first distal coil post 108a in a first direction starting on the first distal coil post 108a post and towards the intersection of the first distal coil post 204a, and the spherical element 202. Subsequent windings start at the intersection of the post 204 and spherical element 202 and wind away from the spherical element 202.
  • a winding “direction” is relative to viewing inwardly along the winding axis toward the position of the attachment of a winding post to the central, spherical element or other central structure.
  • the “first direction” as shown in the example of FIGS. 12A and 12B is a clockwise direction.
  • the wire 102 is wound around the first distal coil post 204a to form the desired degree of winding for the first distal coil 108a, as described herein.
  • the wire 102 is traversed along the spherical element 202 forming the first transition segment 110a to the second distal coil post 108b immediately adjacent to the first distal coil post 108a.
  • the wire 102 is wound around the second distal coil post 204b in a second direction opposite to the first direction (counterclockwise as shown in the example of FIGS. 12A-12B) starting at the intersection of the second distal coil post 204b and the spherical element 202.
  • the wire 102 is wound around the second distal coil post 204b to form the desired degree of winding for the second distal coil 108a, as described herein.
  • the wire 102 is traversed along the spherical element 202 forming the second transition segment 110a to the third distal coil post 204c immediately adjacent to the second distal coil post 204b.
  • the wire 102 is wound around the third distal coil post 204c in a third direction opposite to the second direction (clockwise as shown in the example of FIGS. 12A- 12B) starting at the intersection of the third distal coil post 204c and the spherical element 202.
  • the wire 102 is wound around the third distal coil post 204c to form the desired degree of winding for the third distal coil 108c, as described herein.
  • each of the three other posts 204 can be described at 1/3 rotations as the coil is being wound. Accordingly, a winding of 1-2/3 loops or turns (i.e., 600°) means that as the wire 102 is wound around the post 204, each of the other posts 204, 206 that are passed represents and winding of 1/3 of a loop or turn. Hence, a winding of 1-2/3 loops passes the three other posts 204, 206 once, and then re-passes 2 of the 3 other posts 204, 206 for a total of 1-2/3 loops.
  • a winding of about 2-2/3 (960°) passes each of the other posts 204, 206 twice and then passes the next 2 posts a third time.
  • One of ordinary skill in the art will immediately understand how to determine the correct amount of loops for a mandrel having more than 3 posts 108, such as 4 posts 108, 5 posts 108, etc.
  • the wire is 102 traversed along the spherical element 202 in a next transition segment 110 to a next distal coil post 204 immediately adjacent to the preceding distal coil post 204.
  • the wire is wound around the next distal coil post 204 to form the next distal coil 108, and steps 312-314 are repeated for each additional distal coil post 204.
  • the wire 102 is transitioned along the spherical element 202 to the body post 206.
  • the wire 102 is wound around the body post 206 to form the desired degree of winding for the body portion 106, as described herein.
  • the wire 102 is heat treated to set the secondary configuration of the vaso-occlusive device 100 as wound on the mandrel 200.
  • the wire 102 may then be removed from the mandrel 200, and the wire 102 will take on the secondary configuration having the secondary shape as wound on the mandrel in its relaxed, unconstrained condition.
  • vaso-occlusive device 100 and method 300 for making it, which alleviates the issues of herniation during placement and retention and provides effective framing of the aneurysm, while at the same time have a sufficiently soft and pliable structure that will not rupture the aneurysm, especially small and/or wide-necked aneurysms.
  • the pyramidal shape of the distal coils 108 of vaso-occlusive device 100 has in inherent ability to effectively dissipates forces applied to its apexes, thereby reducing the risk of imparting excessive forces on the walls of the aneurysm which could rupture the aneurysm, including small and/or wide-necked aneurysms.
  • the distal coils are tapered to be inwardly facing and comprise full, closed loops and crossing, overlapping segments which fold more tightly than open loops when deployed in an aneurysm thereby reducing the risk of herniation during placement and retention.
  • shape stability is not compromised because of the inherent ability of the pyramidal shape to dissipate forces applied at the apexes.
  • the pyramidal shaped vaso-occlusive device 100 is more compact than a cube shaped vaso-occlusive device having 8 coils forming the 8 sides of a cube.
  • the volume of the pyramidal shaped vaso-occlusive device 100 has a smaller volume than a cube.
  • the distal coils 108 of the vaso-occlusive device 100 have a smaller diameter than the coils of a cube shaped vaso-occlusive device having the same or substantially same overall height as the vaso-occlusive device 100.
  • each of the distal coils 108 is smaller than the overall height of the vaso-occlusive device 100 (e.g., 2.4 mm diameter of the distal coils vs. a 3.2 mm overall height of the vaso-occlusive device 100.
  • the diameter of the coils of a cube shaped vaso-occlusive device extend the full height of the entire vaso-occlusive device (the height being the length of any one of the sides of the cube shaped vaso-occlusive device.
  • the vaso-occlusive device 100 may also be a component of a vaso-occlusive system 400 which can be used to deploy the vaso-occlusive device 100 into a body cavity, such as an aneurysm 440 (see FIGS. 15-18).
  • the vasoocclusive system 400 comprises a delivery assembly 402 and a vaso-occlusive assembly 404.
  • the delivery assembly 402 may include a delivery catheter 406 and an optional guidewire 408.
  • the vaso-occlusive assembly 404 comprises a vaso-occlusive device 100 and a pusher member 410 detachably coupled to the vaso-occlusive device 100 via a detachment device or junction 412.
  • FIG. 14A shows the vaso-occlusive assembly 404 after it has been slidably disposed within the delivery catheter 406 such that the vasoocclusive device 100 is in its compact, delivery configuration.
  • the delivery catheter 406 is typically an elongated, flexible tube, and can be, for example, a microcatheter or the like.
  • the delivery catheter 406 comprises an elongate sheath body 414 having a proximal portion 416, a distal portion 418 and a lumen 420 extending from the proximal portion 416 to the distal portion 418.
  • the proximal portion 416 of the delivery catheter 406 typically remains outside of the patient and accessible to the clinician when the vaso-occlusive system 400 is used, while the distal portion 418 is sized and dimensioned to reach remote locations of a patient’s vasculature and is configured to deliver the vaso-occlusive device 100 to a body cavity such as an aneurysm.
  • the delivery catheter 406 may also have one or more ports 422 in fluid communication with the lumen 420 for introducing into, or removing fluids from, the sheath body 414.
  • the sheath body 414 may be composed of suitable polymeric materials, metals and/or alloys, such as polyethylene, stainless steel or other suitable biocompatible materials or combinations thereof.
  • the proximal portion 416 may include a reinforcement layer, such as a braided layer or coiled layer to enhance the pushability of the sheath body 414.
  • the sheath body 414 may include a transition region between the proximal portion 416 and the distal portion 418.
  • the vaso-occlusive device 100 may be any of the vaso-occlusive device 100 disclosed herein, having any one or more of the features and aspects described herein.
  • the vaso-occlusive assembly 404 also comprises a pusher member 410.
  • the pusher member 410 is configured to be slidably received within the lumen 420 of the delivery catheter 406.
  • the pusher member 410 has a proximal portion 450, which typically extends proximal of the proximal portion 416 of the delivery catheter 406, and a distal portion 452 which is detachably coupled to the proximal end of the vaso-occlusive device 100 via the detachment device 412.
  • the pusher member 410 may be a coil, wire, tendon, conventional guidewire, torqueable cable tube, hypotube, or the like, having a sufficient columnar strength to permit pushing of the vaso-occlusive device 100 out through distal end 418 of the delivery catheter 406 and into the aneurysmal sac 440 (see FIGS. 17 and 18).
  • the detachment device 412 provides a detachable connection between the pusher member 410 and the vaso-occlusive device 100.
  • the detachment device 412 may comprise an electrolytically detachment, mechanical connector, heat activated detachment, dissolving detachment, or other mechanical, thermal and hydraulic mechanism.
  • the detachment device 412 may be an electrolytically degradable segment for electrolytically decoupling the vaso-occlusive device 100 from the pusher member 410.
  • the optional guidewire 408 of the delivery assembly 402 has a proximal end 444 and a distal end 446.
  • the delivery catheter 406 is advanced over the guidewire 408 with the guidewire 408 disposed within the lumen 420 of the delivery catheter 406.
  • the guidewire 408 extends through only a distal portion of the delivery catheter 406, such as abasexchange lumen.
  • the guidewire 408 is typically used by first advancing the guidewire 408 through the patient’s vasculature to the target insertion site (e.g., the neck 448 of an aneurysm to be filled by the vaso-occlusive device 100, see FIGS. 15-18), and then advancing the delivery catheter 406 over the guidewire 408 to the target insertion site.
  • the target insertion site e.g., the neck 448 of an aneurysm to be filled by the vaso-occlusive device 100, see FIGS. 15-18
  • FIGS. 15-19 an exemplary method 500 of using the vaso-occlusive system 200 to deploy the vaso-occlusive device 100 into an anatomical cavity will now be described.
  • the method 500 will be described with respect to deploying the vaso-occlusive device 100 into an aneurysmal sac 440, as an example.
  • the method 500 is not limited to deploying the vaso-occlusive device 100 into an aneurysmal sac 440, but may be used to deploy the vaso-occlusive device 100, or other medical device as disclosed herein, into any suitable anatomical cavity which is accessible via a patient’s vasculature. Referring to the flow chart of FIG. 19 and FIG.
  • the guidewire 408 is inserted into the patient’s vasculature 442 and is advanced to the target insertion site, namely the aneurysmal sac 440.
  • the use of the guidewire 408 is optional, and is not required in the method 500 of using the vaso-occlusive system 200 to deploy the vaso-occlusive device 100.
  • the delivery catheter 406 of the delivery assembly 402 is advanced over the guidewire 408 until it is positioned with the open distal end 418 adjacent or within the aneurysmal neck 448 of the aneurysm 440, as shown in FIG. 17.
  • the guidewire 408 is pulled out of the delivery catheter 406 leaving the delivery catheter 406 in position.
  • the vaso-occlusive assembly 404 is inserted into the delivery catheter 406 of the delivery assembly 402 and advanced within the delivery catheter 406 to position the distal end of the vaso-occlusive device 100 adjacent the distal portion 418 of the delivery catheter 406, as shown in FIG. 18.
  • the proximal portion 450 of the pusher member 410 remains proximal and outside of the proximal portion 416 of the delivery catheter 406.
  • the vaso-occlusive device 100 Prior to inserting the vaso-occlusive device 100 into the delivery catheter 406, the vaso-occlusive device 100 may be pre-installed in a sheath such that the vaso-occlusive device 100 is in its constrained, delivery configuration (primary configuration).
  • the vasoocclusive device 100 is then inserted into the delivery catheter 406 by placing a distal end of the sheath in abutment with the proximal end 416 of the delivery catheter 406 and extruding the vaso-occlusive device 406 from the sheath into the delivery catheter 406 such that the vaso-occlusive device 100 remains in its delivery configuration within the delivery catheter 206.
  • the vaso-occlusive device 100 is pushed through the lumen 420 of the delivery catheter 406 and distally out of the delivery catheter 406 by pushing on the proximal portion 450 of the pusher member 412.
  • the pyramidal portion 104 is advanced through the aneurysmal neck 448 and into the aneurysmal sac 440, the distal portion of the vaso-occlusive device 100 in its delivery configuration (primary configuration) expands into the secondary configuration (deployed configuration), and the distal coils 108 of the pyramidal portion 104 are formed within the aneurysmal sac 240.
  • the proximal portion of the vaso-occlusive device 100 in its delivery configuration expands into its secondary configuration (deployed configuration) forming the base portion 106 within aneurysmal sac 440.
  • the detachment device 412 is actuated, activated or otherwise operated to detach the vaso-occlusive device 100 from the pusher-member 410.
  • the pusher member 410 is removed from the patient’s vasculature 442 by withdrawing it out through the delivery catheter 406. If the single vaso-occlusive device 100 is sufficient to fill and occlude the aneurysm sac 440, then the method 500 proceeds to step 520 in which the delivery catheter 406 is removed from the patient’s vasculature 442. If multiple vaso-occlusive devices 100 are being implanted, then the process of steps 508-516 are repeated to deliver a sufficient number of vaso-occlusive devices 100 to fill and occlude the aneurysmal sac 440. After the sufficient number of vasoocclusive devices 100 are implanted in the aneurysmal sac 440, the delivery catheter 406 is removed at step 520.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Surgical Instruments (AREA)
PCT/US2022/078935 2021-11-19 2022-10-28 Vaso-occlusive devices and methods for making and using same Ceased WO2023091852A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES22831035T ES3024240T3 (en) 2021-11-19 2022-10-28 Vaso-occlusive devices and methods for making same
JP2024529178A JP2024540455A (ja) 2021-11-19 2022-10-28 血管閉塞デバイスおよびその製造方法および使用方法
CN202280071603.3A CN118175965A (zh) 2021-11-19 2022-10-28 血管闭塞设备及其制造和使用方法
EP22831035.5A EP4432932B1 (en) 2021-11-19 2022-10-28 Vaso-occlusive devices and methods for making same
US18/667,790 US20240299035A1 (en) 2021-11-19 2024-05-17 Vaso-occlusive devices and methods for making and using same
US19/195,670 US20250255611A1 (en) 2021-11-19 2025-04-30 Vaso-occlusive devices for occluding blood vessels and methods for making and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163281561P 2021-11-19 2021-11-19
US63/281,561 2021-11-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/667,790 Continuation US20240299035A1 (en) 2021-11-19 2024-05-17 Vaso-occlusive devices and methods for making and using same

Publications (1)

Publication Number Publication Date
WO2023091852A1 true WO2023091852A1 (en) 2023-05-25

Family

ID=84688536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/078935 Ceased WO2023091852A1 (en) 2021-11-19 2022-10-28 Vaso-occlusive devices and methods for making and using same

Country Status (6)

Country Link
US (1) US20240299035A1 (https=)
EP (1) EP4432932B1 (https=)
JP (1) JP2024540455A (https=)
CN (1) CN118175965A (https=)
ES (1) ES3024240T3 (https=)
WO (1) WO2023091852A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118512228A (zh) * 2024-05-14 2024-08-20 北京巨源仁通医疗科技有限公司 一种封堵器

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994069A (en) 1988-11-02 1991-02-19 Target Therapeutics Vaso-occlusion coil and method
US20190298387A1 (en) * 2016-05-13 2019-10-03 Covidien Lp Aneurysm treatment coils

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171326B1 (en) * 1998-08-27 2001-01-09 Micrus Corporation Three dimensional, low friction vasoocclusive coil, and method of manufacture
US6159165A (en) * 1997-12-05 2000-12-12 Micrus Corporation Three dimensional spherical micro-coils manufactured from radiopaque nickel-titanium microstrand
EP4529863B1 (en) * 2021-11-11 2026-04-15 Stryker Corporation Vaso-occlusive devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994069A (en) 1988-11-02 1991-02-19 Target Therapeutics Vaso-occlusion coil and method
US20190298387A1 (en) * 2016-05-13 2019-10-03 Covidien Lp Aneurysm treatment coils

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118512228A (zh) * 2024-05-14 2024-08-20 北京巨源仁通医疗科技有限公司 一种封堵器

Also Published As

Publication number Publication date
CN118175965A (zh) 2024-06-11
EP4432932B1 (en) 2025-03-12
US20240299035A1 (en) 2024-09-12
JP2024540455A (ja) 2024-10-31
ES3024240T3 (en) 2025-06-04
EP4432932A1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US20200000477A1 (en) Embolization Plug
CN104168844B (zh) 血管内设备
US20240374261A1 (en) Vaso-occlusive devices and methods for making and using same
JP7512497B2 (ja) 血管閉塞デバイス
CN101472537A (zh) 柔软的血管闭塞装置
US20240299035A1 (en) Vaso-occlusive devices and methods for making and using same
WO2022042345A1 (zh) 血管瘤封堵装置、血管瘤封堵治疗装置及血管瘤封堵系统
US20250255611A1 (en) Vaso-occlusive devices for occluding blood vessels and methods for making and using same
EP4398814B1 (en) Vaso-occlusive device
CN115721366A (zh) 一种中空结构栓塞弹簧圈组件及推送系统

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22831035

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202447024993

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 202280071603.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2024529178

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022831035

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022831035

Country of ref document: EP

Effective date: 20240619